Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.48 |
| ▸ | TACR1 | P25103 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159016 | 0.85 | REN (0.48) | RENTACR1MAPT | |
| SCHEMBL5161677 | 0.81 | TACR1 (0.70) | TACR1MAPT | |
| Hydrochloric Acid SCHEMBL4492786 | 0.81 | TACR1 (0.69) | TACR1MAPT | |
| Hydrochloric Acid SCHEMBL4492783 | 0.81 | TACR1 (0.69) | TACR1MAPT | |
| Hydrochloric Acid SCHEMBL4492777 | 0.81 | TACR1 (0.69) | TACR1MAPT | |
| SCHEMBL6959998 | 0.76 | REN (0.76) | REN | |
| SCHEMBL9025108 | 0.75 | TACR1 (0.68) | TACR1MAPT | |
| SCHEMBL7881454 | 0.75 | TACR1 (0.68) | TACR1MAPT | |
| SCHEMBL9025119 | 0.75 | TACR1 (0.68) | TACR1MAPT | |
| SCHEMBL7881450 | 0.75 | TACR1 (0.68) | TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | REN 610/4885TACR1 2/4885MAPT 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.